Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prescient Therapeutics Limited ( (AU:PTX) ) has issued an announcement.
Prescient Therapeutics Limited announced the cessation of 1,000,000 securities under the ASX code PTXAK due to the expiry of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and future growth prospects.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company is engaged in creating targeted and personalized treatment options to improve patient outcomes in oncology.
Average Trading Volume: 956,637
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$33.82M
Find detailed analytics on PTX stock on TipRanks’ Stock Analysis page.